A prospective, randomised, comparative study of efficacy and safety among sodium valproate, topiramate and flunarizine plus propranolol combination in migraine prophylaxis in a tertiary care hospital in west bengal

Ratul Banerjee0 个研究点目标入组 108 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•l. Patients diagnosed with migraine, according to the 3rd edition of International Classification of Headache Disorders III criteria of International Headache Society .
•2. Presence of an indication for prophylactic treatment that is intolerable headache attacks that were either debilitating or resulted in significant loss of daily function, frequent attacks that is more than 4 attacks per month.
•3. Adult and adolescent of age more than 12 years.
•4. Drug naive patients that is no history of proper anti-migraine treatment.

•l. Patients with headache causes other than migraine such as cluster headache, headache caused by space occupying lesions, etc will be excluded.
•2. Patients having migraine with other comorbidities.
•3. Patients having baseline ECG changes, having dyslipidemia. Creatinine level more
•thanl.5mg/dl, and SGOT &SGPT level more than thrice the normal, FPG more than l26mgldl and PPG more than 2OOmg/dl.
•4. Patients with concomitant major medical or psychiatric disorder on first evaluation e.g. major
•depression, psychosis, dementia, etc.
•5. Pregnant and lactating mother.
•6. Any known allergy or contraindications to the study drug or drugs.

发起方

Ratul Banerjee